Max Drawdown (5Y) Chart

View Max Drawdown (5Y) for AMRN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Max Drawdown (5Y) Chart
Start Trial

Historical Max Drawdown (5Y) Data

View and export this data back to 1993. Start Trial.
Date Value
July 31, 2026 98.07%
June 30, 2026 98.07%
May 31, 2026 98.07%
April 30, 2026 98.07%
March 31, 2026 98.07%
February 28, 2026 98.07%
January 31, 2026 98.07%
December 31, 2025 98.07%
November 30, 2025 98.07%
October 31, 2025 98.07%
September 30, 2025 98.07%
August 31, 2025 98.07%
July 31, 2025 98.07%
June 30, 2025 98.07%
May 31, 2025 98.07%
April 30, 2025 98.07%
March 31, 2025 98.07%
February 28, 2025 98.07%
January 31, 2025 98.07%
December 31, 2024 98.07%
November 30, 2024 98.07%
October 31, 2024 97.65%
September 30, 2024 97.65%
August 31, 2024 97.49%
July 31, 2024 97.40%
Date Value
June 30, 2024 97.40%
May 31, 2024 97.26%
April 30, 2024 97.26%
March 31, 2024 97.26%
February 29, 2024 97.26%
January 31, 2024 97.26%
December 31, 2023 97.26%
November 30, 2023 97.26%
October 31, 2023 97.16%
September 30, 2023 96.50%
August 31, 2023 95.81%
July 31, 2023 95.56%
June 30, 2023 95.56%
May 31, 2023 95.56%
April 30, 2023 95.56%
March 31, 2023 95.56%
February 28, 2023 95.56%
January 31, 2023 95.56%
December 31, 2022 95.56%
November 30, 2022 95.56%
October 31, 2022 95.56%
September 30, 2022 95.48%
August 31, 2022 95.32%
July 31, 2022 95.32%
June 30, 2022 95.32%

Max Drawdown Definition

Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.

Read full definition.

Max Drawdown (5Y) Range, Past 5 Years

View Max Drawdown (5Y) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Max Drawdown (5Y) Benchmarks

View Max Drawdown (5Y) Benchmarks
Start Trial
Neurocrine Biosciences, Inc. 46.39%
Cellectis SA 97.08%
Alkermes Plc 68.08%
Akari Therapeutics Plc 99.83%
Liquidia Corp. 93.87%